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Abstract
It has been more than a decade that the term “Translational” (medicine, Research, Science) has trickled through the
minds of academics, clinicians, business persons, regulators, policy makers, patients and their families, patient
advocates, politicians and the public. Although the term means different things for different stake holders, it reflect
and eagerness to see a fruitful outcome of the resources invested in biotechnology to benefit primarily the
patients but also provide financial return for those who invested. Skeptics remain who feel the concept if abused
by those attempting to deviate funds for basic or clinical research to a new domain performing similar tasks under
a different egida. In reality, translational sciences are not different in scope any from previous efforts to focus the
goals of research toward the relevant object of helping the disabled. The difference is that, in recent decades,
awareness has risen about the difficulties of reaching this goal. In particular, it has become clear that the difficulties
are not limited to scientific challenges, but to a myriad of hurdles that make testing and licensing of novel
concepts unnecessarily burdensome. Moreover, it was recognized that the infrastructure to support clinical research
is frequently outdated and inappropriate. The biggest hurdle, however, remains the cost and the length of clinical
testing that could prolong of decades the application of even the most successful treatments. As for any
expanding field, a plethora of journals has appeared with “Translational” in their title. This is a positive sign of the
growth in interest for the field and the need to respond to a need for editorial boards competent in the
challenges of judging clinical testing. In this editorial, we will discuss the meaning of translational medicine, its
goals and needs; we will summarize the remaining challenges and will provide a personal overview of the
strategies that remain to be implemented.
The public health and the health care challenge
It is expected that life expectancy will progressively
increase as it has in the last decades [1]. As a consequence,
the prevalence of chronic diseases, which affect predomi-
nantly the elderly, is expected to grow [2]. This will result
in a formidable challenge for the health care system as
chronic conditions last for a long time and require, as a
consequence, prolonged spending with marginal benefit
for the patient. Although the gross domestic product of a
given Country is directly correlated with prolonged life
expectancy [3] the relationship plateaus at the upper end
of GDP values. Thus, and it is inaccurate to assume that
the more it is spent in Health the better the results.
A recent analysis from the United States of America Con-
gressional Budget Office in fact suggested an inverse rela-
tionship between spending for treatment and a composite
measure of quality of care [4]. Yet, the United States
spending for health care continues to expand and it is pro-
jected to reach the paradoxical figure of almost 100% of
the gross domestic product by the end of the this century.
It could be argued that better patient selection and
enhancement of treatment effectiveness may decrease the
costs. Thus, it is not only in the patient interest but in the
interest of the health care provider to spend a meager pro-
portion of the astronomic health care spending in research
and development relevant to these goals: this is one of the
fundamental values of translational sciences.
The need for translational sciences
It has been suggested that translational sciences are just a
“fad"; a passing spree of introspection toward an utopist
goal. In reality, translational sciences reflects quite specific
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needs that will stay relevant (independently of the term
used) till they will be met. The need for translational
sciences resides in 1) the need to find cost/effective solu-
tions to the treatment of chronic diseases which in turn
represent 2/3 of heath care spending in most countries; 2)
the high throughput of modern biotechnology exponen-
tially supplying novel diagnostic and therapeutic opportu-
nities requiring efficient testing for their validation in
humans; 3) the lack of accurate pre-clinical models and
surrogate markers that could speed the testing of candi-
date products bypassing the overwhelming cost and length
of clinical testing particularly for chronic diseases where
long term benefit such as survival can be assessed in
decades.
The definition and goals of translational sciences
Translational sciences, also referred to as translational
medicine or translational research, are interpreted differ-
ently according to the stake holder. For patients, clinicians,
heath care providers, it refers to the need of accelerating
the capture of the benefit of biomedical research. For the
academic, translational sciences refers to the desire of con-
firming and validating novel concepts and identify new
ones. For the commercial sector the term defines a process
aimed at expediting the development and commercializa-
tion of known entities. It should be emphasized that
although coming from a different prospective, the defini-
tions are not mutually exclusive and overlap as they reflect
the common need of expediting the discovery and valida-
tion process. Thus, we prefer to align the definition of
translational sciences with their goals. On our account, the
goals of translational sciences are to improve therapeutic
outcomes by: validating the potential of novel discoveries
while identifying in the process of clinical testing novel
concept relevant to human disease through direct human
observation. Some feel that the term “translational” was
invented to redirect funds from other disciplines without
providing any true conceptual advance. It is true that simi-
lar terms have been used in the past such as: pre-clinical
research, clinical research, evidence-based research, dis-
ease-targeted research. And it is true that these terms
reflect the same goals. Thus, translational medicine is not
pretending to discover new goals and values but its
essence resides more in emphasizing the need to enhance
the efficiency of discovery validation recognizing the
increasing obstacles. As we previously suggested, the goals
are not unique to translational sciences, as basic scientists
as well as physicians scientist share them; however, trans-
lational scientist, perhaps more than other, are focused
and have the expertise to indentify and confront the chal-
lenges at the interface between basic and clinical investiga-
tion proposing integral solutions to increase the efficiency
of the process. To quote a previous manuscript of ours:
“The traditional goals of biomedical research function as a
substrate for the catalytic activity of translational research
that, like an enzyme, is aimed at enhancing the efficiency
rather than modifying the process“ [5].
The challenges and potential solutions
We have extensively discussed in the past the challenges
to the efficient development and validation of useful thera-
peutics [5-8]. We will limit the discussion the most out-
standing; the first it the financial support of translational
sciences. It should be emphasized that the problem is dif-
ferent for academia and the commercial sector. The com-
mercial sector is not lacking funds but the problem is the
containment of the cost of performing broad based clinical
trials that could lead to licensing. Thus, the challenge for
the commercial sector is reduction in spending. The
bureaucratization of clinical research is clearly jeopardiz-
ing these efforts unnecessarily and something needs to be
done to reduce the burden of clinical experimentation [5].
Better pre-clinical testing to guide the selection and pre-
dict accurately the effectiveness of therapeutics could also
decrease costs. Furthermore, the identification of surrogate
biomarkers that could predict the long term effectiveness
of treatment (on survival) early on during a clinical trial
could alleviate the costs but shortening the length of clini-
cal investigations unlikely to be successful. These of
course, are not new concepts but they remain a priority
and something translational scientists should continue to
focus as a priority. Yet, it is our contention that very little
is done in clinical investigation to understand the mechan-
ism of action of drugs in humans and identify causes of
failure. We believe that clinical trials are still conducted
sparingly with the minimal goal of testing clinical effective-
ness as dictated by regulatory agencies to justify licensing
but with little intent to identify causes of failure of a given
treatment. In particular, little use is done of high through-
put technologies that could provide mechanistic insights
beyond those predicted by the trial conceptualization. We
strongly believe that the bedside-to-bench direction of
translational sciences remains under appreciated [8,9].
For academia the challenges are different and revolve
around lack of funding; the proportions between spend-
ing to test a new concept in experimental settings are
logarithmically less than those spent to validate the same
further in the clinics. Few hundred thousand dollars may
help a basic scientist provide a proof of concept that a
new strategy is worth being investigated in the clinics;
this is little money compared to the billions of dollars
spend by the commercial sector to license a product. Yet,
such funding is not easy to obtain. We suggest that the
solution is not to compete with other academic entities
such as the basic sciences but rather to identify alterna-
tive sources through public education [10] and through
partnership with the commercial sector [11]. Indeed, aca-
demia can provide broader support to biotechnology
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development than the focused efforts of the biopharma-
ceutical industry and, as a consequence, play a comple-
mentary role. This applies particularly to the realm of
entrepreneurship. A modern translational medicine cen-
ter could provide expertise and facilities to help small
biotechnology companies who cannot afford to cover all
the aspects of biotechnology. Such partnership could
enhance funding for academia through venture capital
benefiting with its creativity the commercial sector. It
should be emphasized that the proportions between
spending for heath care (in the trillions) compared to the
spending for research by governments (in the millions or
few billions) is astounding. Yet, most of health care
spending is devoted to chronic conditions for which the
treatments are not effective. Wouldn’t it be more logical
to shift the balance toward finding new solutions rather
than spending a large proportion of the gross domestic
product for treatments we know do not work. As Ein-
stein said, it is crazy to keep doing the same thing and
expect different results. For health care, this is the sad
reality.
Of course, there are many more challenges that transla-
tional scientists are facing, such as a fragmented infra-
structure, lack of adequately trained investigators,
bureaucratic and regulatory burdens, lack of support by
the public which may question the value of biomedical
research [12]. Yet the challenge remains in our conduct
first [8]. It behooves to the translational scientists to chal-
lenge the status quo, and not to accept compromises by
educating the public, patients’ advocates, basic scientists,
ethicists, regulatory agencies and politicians [10]. Only by
changing the way translational scientists will conduct
their own efforts and providing examples and proofs of
principle they will be able to affect the necessary changes.
Why a new journal of translational research
A way to chance it to provide a forum for discussion; in
the last decade, several journal have emerged with the
“translational” in the title reflecting this need for change.
Even the American Association for the Advancement of
Science has recognized this need [13]. Is there too much
redundancy? Translational sciences represent a broad
approach to biomedical research and do not cover specia-
lized areas; thus, journals do not compete but rather pro-
vide broadening opportunities to disseminate ideas
through editorial boards sympathetic to clinical investiga-
tion. Considering the plethora of basic science journals
promoting important aspects of biomedical research but
not directly relevant to public health, it is important that
alternative venues are provided to clinical scientists; this is
particularly important at the interface between basic and
clinical investigation where the scientific output may not
satisfy traditional editorial practices focus on elegance
rather than usefulness. The job of the editor is critical and
the ethical burden not to be underestimated. By not deny-
ing review to a manuscript, the editor assumes a responsi-
bility that goes beyond the preference of the journal but
may affect how biomedical research is rewarded and sup-
ported in the future. Paradoxically, those who passively
receive the output of the scientific process become arbiters
of future trends. Prestigious journal molded a field of ele-
gance that has failed, however, to produce tangible results
as most complex diseases are still uncured [14,15]. It is the
task of the new journals dedicated to clinically relevant
investigations to reshape the way biomedical research is
perceived and rewarded. Each translational sciences jour-
nal will have the task to pursue, in unison with its peers,
the fair assessment of clinical research that, perhaps less
elegant and pristine than controlled laboratory investiga-
tions, will provide the much needed insights about the rea-
lities of human disease.
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